Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) announced a Notice of Allowance from the USPTO for its patent application on trehalose (SLS-005). This patent covers methods to treat various neurodegenerative diseases, including spinocerebellar ataxia and frontotemporal dementia. Trehalose is known for its ability to cross the blood-brain barrier and activate autophagy, which may help reduce protein aggregation in cells. The allowance of this patent is a significant step for Seelos in its development of therapies targeting central nervous system disorders.

Positive

• Receipt of Notice of Allowance from the USPTO for trehalose patent.
• Patent covers methods for treating multiple neurodegenerative diseases.
• Trehalose has demonstrated potential in reducing protein aggregation.

Negative

• None.

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' application number 16/460,046 titled: "TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE".

The allowed claims cover a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasaldegeneration (CBD), progressive supranuclear palsy (PSP), and frontotemporal dementia.

About Trehalose
Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier, stabilizes proteins, and importantly activates autophagy which is the process that clears material from cells. In several animal models of diseases, associated with abnormal cellular protein aggregation or storage of pathologic material, it has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-receives-notice-of-allowance-for-an-additional-us-patent-for-trehalose-sls-005-301126928.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is Seelos Therapeutics' recent patent news?

Seelos Therapeutics received a Notice of Allowance from the USPTO for a patent on trehalose (SLS-005) to treat neurodegenerative diseases.

What diseases can trehalose potentially treat according to Seelos' new patent?

The patent covers treatments for spinocerebellar ataxia, frontotemporal dementia, and several other neurodegenerative diseases.

When did Seelos Therapeutics announce the patent allowance?

The announcement was made on September 10, 2020.

What is the significance of the trehalose patent for Seelos?

The allowed patent is a crucial advancement for Seelos in developing therapies for central nervous system disorders.